EVALUATION OF HEPATOCYTE-SPECIFIC PARAMAGNETIC CONTRAST-MEDIA FOR MR-IMAGING OF HEPATITIS

被引：12

作者：

TANIMOTO, A

KREFT, BP

BABA, Y

ZHAO, LH

FINN, JP

COMPTON, CC

STARK, DD

机构：

[1] Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

[2] Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

[3] Department of Radiology, New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts

[4] Department of Radiology, University of Bonn

[5] Department of Radiology, Kumamoto University

[6] Department of Radiology, University of Massachusetts Medical Center, Worcester, Massachusetts

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1993年 / 3卷 / 05期

关键词：

CONTRAST ENHANCEMENT; CONTRAST MEDIA; COMPARATIVE STUDIES; GADOLINIUM; HEPATITIS; LIVER; DISEASE; MR; MANGANESE; RELAXOMETRY;

D O I：

10.1002/jmri.1880030515

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The hepatocyte-specific paramagnetic magnetic resonance (MR) contrast agents manganese-DPDP [N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'bis-(phosphate)] and gadobenate dimeglumine were used for diagnosing chemically induced hepatitis in rats. Ex vivo liver tissue relaxation times and in vivo MR image signal-to-noise ratios were compared before and after contrast agent administration. Ex vivo relaxometry and in vivo MR imaging showed that Mn-DPDP enhanced normal and diseased livers to the same degree at all time points from 5 to 120 minutes. Gadobenate dimeglumine showed reduced T1 and T2 enhancements in hepatitis relative to those of normal liver, in the early phase (5-30 minutes). However, these effects are offsetting, and as a result, MR imaging failed to allow distinction of diseased from normal livers. This surprising result observed in vivo was in fact predicted by applying the Bloch equation to our ex vivo data. Our results show that detection and quantitation of hepatitis with MR imaging enhanced with paramagnetic cell-specific contrast agents will be more difficult than anticipated.

引用

页码：786 / 793

页数：8

共 34 条

[1]

Combes B, Schenker S, Laboratory tests, Diseases of the liver, pp. 259-302, (1982)

[2]

Ratner AV, Carter EA, Pohost GM, Wands JR, Nuclear magnetic resonance spectroscopy and imaging in the study of experimental liver diseases, Alcohol Clin Exp Res, 10, pp. 241-245, (1986)

[3]

Stark DD, Bass NM, Moss AA, Et al., Nuclear magnetic resonance imaging of experimentally induced liver disease, Radiology, 148, pp. 743-751, (1983)

[4]

Herfkens R, Davis P, Crooks L, Et al., Nuclear magnetic resonance imaging of the abnormal live rat and correlation with tissue characteristics, Radiology, 141, pp. 211-218, (1981)

[5]

Doyle FH, Pennock JM, Banks LM, Et al., Nuclear magnetic resonance imaging of the liver: initial experience, AJR, 138, pp. 193-200, (1982)

[6]

Reva RC, Chen DCP, Fajman WA, Hepatic scintigraphy, Hepatic radiography, pp. 50-81, (1984)

[7]

Pauwels S, Piret L, Schoutens A, Vandermoten G, Beckers C, Tc‐99m‐diethyl‐IDA imaging: clinical evaluation in jaundiced patients, J Nucl Med, 21, pp. 1022-1028, (1980)

[8]

Vera DR, Krohn KA, Stadalnik RC, Scheibe PO, Tc‐99m‐galactosyl‐neoglycoalbumin: in vivo characterization of receptor mediated binding to hepatocytes, Radiology, 151, pp. 191-196, (1984)

[9]

Stadalnik RC, Vera DR, Woodle S, Et al., Technetium‐99m NGA functional hepatic imaging: preliminary clinical experience, J Nucl Med, 26, pp. 1233-1242, (1985)

[10]

Chervu LR, Nunn AD, Loberg MD, Radiopharmaceuticals for hepatobiliary imaging, Semin Nucl Med, 12, pp. 5-17, (1982)

← 1 2 3 4 →